
    
      The Phase 1b lead-in portion of the study was conducted to determine the MTD of OMP-59R5
      administered along with EP. The Phase 2 portion of the study was multi-center, randomized,
      and placebo-controlled. Subjects who qualified for enrollment into the Phase 2 portion of the
      study were randomized in a 1:1 ratio to receive study treatment of tarextumab along with EP
      (Arm A) or placebo along with EP (Arm B).
    
  